USP8 and neoplasm: To explore the anti-tumor role of the USP8 inhibitor via regulation of PD-L1 levels in vivo, we constructed tumor models and administrated the USP8 inhibitor alone or combined with αPD-L1 to mice bearing subcutaneous KPC-derived tumors (Fig. 5a).